Phase 2 N=233 The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)
Pelvic Inflammatory Disease
Primary: Clearance of Anaerobic Organisms From the Endometrium — 14; 18; 7; 1 participants — p=0.046
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=23 A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Liver Cirrhosis · Hepatic Cirrhosis · Portal Hypertension
Primary: Hepatic Venous Pressure Gradient (HVPG) — 15.2; 8.05; 20.62; 14.1 mmHg — p=0.257
Phase 2 N=7 A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations
Autosomal Dominant Hypocalcemia (ADH)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 3; 1 participants
Phase 2 N=18 Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Indolent Non-Hodgkin's Lymphoma · Follicular Lymphoma · Small Lymphocytic Lymphoma
Primary: Overall Safety of Idelalisib — 88.9; 27.8; 55.6; 83.3 percentage of participants
Phase 2 N=21 Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
Mouth Neoplasms
Primary: Change in IL-2 Levels — 1.8; 4.0; 7.9; 2.1 pg/100 gm protein — p=<0.05
Phase 2 N=91 A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia
Anemia
Primary: Median Change From Baseline in Hemoglobin Levels to End of Initial Treatment Under Constant Dosing Regimen — -0.29; -0.92; -0.04; -0.46 g/dL
Phase 2 N=137 A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.
Anemia
Primary: Median Change From Baseline in Hemoglobin Levels to End of Initial Treatment Under Constant Dosing Regimen — -0.80; -0.60; -0.29; 0.02 gram per deciliter
Phase 2 N=24 Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease
Sickle Cell Disease
Primary: Change in Frequency of Vaso-occlusive Pain Events, Before and After Treatment With Simvastatin — 0.2365; 0.1311 proportion of pain days — p=0.005
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Malignant Brain Tumors
Primary: Number of Participants With Objective Response — 2; 2; 4; 19 Participants
Phase 2 N=129 S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Progression Free Survival (PFS) — 3.5; 3.0 months — p=0.49
Phase 2 N=15 Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck
Carcinoma, Adenoid Cystic · Head and Neck Neoplasms
Primary: Tumor Progression — 0; 0; 7; 4 Participants
Phase 2 N=31 N-acetylcysteine (NAC) for Children With Tourette Syndrome
Tourettes Syndrome · Tic
Primary: Improvement in Tic Severity — 24.3; 21.3 units on a scale
Phase 2 N=250 Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
Post Menopausal Osteoporosis
Primary: Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 Months — 1.87; 2.33; 2.95; 5.80 Percent change — p=0.0066
Phase 2 N=137 A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) — 32; 21; 23 percentage of participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Brain Tumors
Refractory Brain Tumors
Primary: Number of Participants With Objective Response — 4; 5; 12; 10 Participants